Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus

被引:7
|
作者
Bayomy, Omar [1 ]
Rao, Ajay D. [1 ,2 ,3 ,4 ]
Garg, Rajesh [1 ,2 ]
Vaidya, Anand [1 ,2 ]
Kotin, Alyssa R. [2 ]
Reiber, Beata [5 ]
Nijmeijer, Stephanie [5 ]
Di Carli, Marcelo F. [1 ,5 ,6 ]
Jerosch-Herold, Michael [1 ,5 ]
Kwong, Raymond Y. [1 ,6 ]
Adler, Gail K. [1 ,2 ]
机构
[1] Harvard Med Sch, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, 221 Longwood Ave, Boston, MA 02115 USA
[3] Lewis Katz Sch Med, Sect Endocrinol Diabet & Metab, Philadelphia, PA USA
[4] Lewis Katz Sch Med, Ctr Metab Dis Res, Philadelphia, PA USA
[5] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[6] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
type; 2; diabetes; plasminogen activator inhibitor-1; pericardial fat; adipose tissue; EPICARDIAL ADIPOSE-TISSUE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; PAI-1; ASSOCIATION; HEART; DYSFUNCTION; EXPRESSION; PREVENTION;
D O I
10.1089/met.2017.0031
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Plasminogen activator inhibitor-1 (PAI-1) is implicated in the pathophysiology of cardiovascular disease (CVD) and increased in individuals with type 2 diabetes mellitus (T2DM). Adipose tissue produces PAI-1, and pericardial fat is a CVD risk factor. We sought to determine the relationship between PAI-1 and pericardial fat in males and females with well-controlled T2DM. Methods: The study population consisted of 32 males and 19 females, aged 35-70 years with T2DM, without clinical evidence of CVD or other active medical problems except for hypertension. Subjects were studied under good cardiometabolic control. Study procedures included fasting blood work and cardiovascular imaging. Cardiac magnetic resonance imaging of the heart was used to identify and quantify pericardial fat from the bifurcation of the pulmonary trunk to the last slice containing cardiac tissue. Results: PAI-1 was positively correlated with pericardial fat (beta = 0.72, r = 0.72, P < 0.001) as well as with homeostatic model assessment of insulin resistance (r = 0.31, P = 0.03) and serum triglycerides (r = 0.27, P = 0.05). In a multivariable regression model, controlling for insulin sensitivity, triglycerides, and body mass index, pericardial fat was independently associated with PAI-1 (beta = 0.80, P < 0.001). Conclusions: PAI-1 is positively associated with pericardial fat in individuals with T2DM.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 50 条
  • [31] PLATELET PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN PATIENTS WITH TYPE-II DIABETES
    JOKL, R
    LAIMINS, M
    KLEIN, RL
    LYONS, TJ
    LOPESVIRELLA, MF
    COLWELL, JA
    DIABETES CARE, 1994, 17 (08) : 818 - 823
  • [32] PLASMA LEVELS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN PATIENTS WITH TYPE 2 DIABETES AFTER LIPOPOLYSACCHARIDE INJECTION
    Berg, R. M. G.
    Andreasen, A. S.
    Pedersen, B. K.
    Moller, K.
    INTENSIVE CARE MEDICINE, 2009, 35 : 244 - 244
  • [33] Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
    Johansson, L
    Jansson, JH
    Boman, K
    Nilsson, TK
    Stegmayr, B
    Hallmans, G
    STROKE, 2000, 31 (01) : 26 - 32
  • [34] Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes
    Brazionis, L.
    Yau, J.
    Rowley, K.
    Itsiopoulos, C.
    O'Dea, K.
    Wong, T. Y.
    Jenkins, A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (02) : 192 - 199
  • [35] Effect of Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin on Plasminogen Activator Inhibitor-1 in Patients With Diabetes Mellitus
    Tani, Shigemasa
    Takahashi, Atsuhiko
    Nagao, Ken
    Hirayama, Atsushi
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 115 (04): : 454 - 460
  • [36] Plasminogen activator inhibitor-1 has a circadian rhythm in blind individuals
    Schoenhard, JA
    Muldowney, JA
    Emens, JS
    Lewy, AJ
    Vaughan, DE
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : E103 - E103
  • [37] Polymerization of plasminogen activator inhibitor-1
    Zhou, A
    Faint, R
    Charlton, P
    Dafforn, TR
    Carrell, RW
    Lomas, DA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) : 9115 - 9122
  • [38] Plasminogen Activator Inhibitor-1 in Aging
    Yamamoto, Koji
    Takeshita, Kyosuke
    Saito, Hidehiko
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (06): : 652 - 659
  • [39] Plasminogen activator inhibitor-1 and the kidney
    Eddy, AA
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (02) : F209 - F220
  • [40] PLASMINOGEN-ACTIVATOR INHIBITOR-1
    LOSKUTOFF, DJ
    MIMURO, J
    HEKMAN, C
    THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 534 - 534